## 3 PDT in Veterinary Oncology
### Other Tumors  
Other types of tumors and some reports that are unclear regarding the histological type of tumors addressed are included in this section. HPD (2.5 mg/kg) was used to treat a cat's lip eosinophil granuloma. A complete therapeutic response was seen, with the animal showing a complete response up to 6 months of follow-up and being considered cured eight months later. In the same study, a dog with \begin{table}
\begin{tabular}{p{42.7 pt} p{113.8 pt} p{113.8 pt} p{113.8 pt} p{113.8 pt}} \hline \hline
**Ref.** & **Neoplasm** & **Patients** & **PDT Protocol** & **Main Results** \\ \hline
[79] & Melanoma, hard palate & 1 Dog & **PS:** HPD, 2.5 mg/kg, iv & \(\bullet\) & The patient showed a complete response at 6 months; considered ct the last follow-up (8 months) \\ \hline
[96] & Melanoma, sclera & 1 Dog & **PS:** EtNBS, 2.0 mg/kg, iv & \(\bullet\) & No response to therapy Reported hyperthermia and vomiting during infusion \\ \hline
[84] & Melanoma, soft palate & 1 Dog & **PS:** ZnPCS4, 0.25 mg/kg, iv & \(\bullet\) & Free of disease 1 year after PDT without any subsequent treatment \\ \hline
[125] & Melanoma, eyelid & 1 Cat & **PS:** AO, 1 \(\upmu\)g/mL, tumor bed & \(\bullet\) & At 14 months postoperatively, metastases were distributed \\  & & & **PS:** AO, 1 \(\upmu\)g/mL, tumor bed & \(\bullet\) & At 16 months, the cat died, but on necroops, recurrence was not 400–700 nm, 2 sessions & \(\bullet\) & At 16 months, the cat died, but on necroops, recurrence was not 4 detected at the original tumor site \\ \hline  & & & & & \\  & & & & & \\  & & & & & \\  & & & & & \\  & & & & & \\ \end{tabular}
\end{table} 
Table 4: Clinical studies on PDT in animals with melanomas. \begin{table}
\begin{tabular}{p{42.7 pt} p{113.8 pt} p{113.8 pt} p{113.8 pt} p{113.8 pt}} \hline \hline
**Ref.** & **Neoplasm** & **Patients** & **PDT Protocol** & **Main Results** \\ \hline
[124] & \multirow{4}{*}{Sarcomas} & & **PS:** Porfimer sodium, 3.0 mg/kg, iv; AICIPc, 0.175–0.589 mg/kg, iv; SnET2, 0.83 mg/kg, iv & \(\bullet\) & Independent of photosensitizers uptake and light dose, more photon absorption is needed to induce tumor necrosis \\ \hline  & & & **Light:** Argon laser, 150–280 J/cm\({}^{2}\), 1 session & \(\bullet\) & Tumor necrosis \\ \hline  & & & & \\ \hline  & & Legend: 5-ALA, 5-aminolevulinic acid; AICIPc-nano, aluminum-chloride-phthalocyanine nanoemulsion; AO, acridine orange; BPD-MA, benzoporphyrin derivative monoacid ring A; CASPc, chloro-aluminum sulfonated phthalocyanine; HPD, hematoporphyrin derivative; HPPH, pyropheophorbide-a-hexyl ether; ICG, indocyanine green; iv; intravenous; PS, photosensitizer; ZnPCS4, zinc phthalocyanine tetrasulfonate. \\ \hline \hline \end{tabular}
\end{table} 
Table 3: _Cont._sebaceous glands adenoma of the ear was given treatment. In this case, a complete response was achieved. Irradiation was performed with an Argon laser at 288 J/cm\({}^{2}\) (631 nm) [79]. Mammary gland tumors in cats and dogs were submitted to 5-ALA-based PDT. The two cats showed partial response and stable disease [71]. The disease progressed in a dog treated in combination with Lapatinib [71]. Progressive disease was also observed in a dog with myeloma, undergoing simultaneous therapy with mephalan [71]. Two dogs with ameloblastoma were treated with BPD-MA, and a change in the color of the tumor and tumor necrosis was observed after a few days in the PDT-treated animals. Moreover, a tumor-free interval of up to 7 months was observed, and a potential anti-angiogenic effect was demonstrated [105]. ZnPCs\({}_{4}\) was used in a dog with viral papilloma in the mouth and vulva, which showed a partial response to PDT and neutropenia of unknown cause [84]. One dog with spontaneous advanced primary prostate cancer was prepared for surgery and PDT with palladium-bacteriopheophorbide (Tookad, WST09, 2 mg/kg, iv). Light (diode laser, 763 nm) was applied to a total light dose of 100-150 J/cm. The dog survived one week of postsurgical and PDT procedures.